
Background The cardiac proteome responds to various physiological and pathological stimuli. While acute left ventricle (LV) unloading by catheter-based LV assist device is now a therapeutic option for heart failure, its impact on cardiac proteins is unknown. We sought to characterize proteomic remodeling associated with altered LV load in ischemic heart failure. Methods Sixteen Yorkshire pigs underwent myocardial infarction (MI) and were subjected one week later to either 2-hour acute mechanical LV unloading (n = 6), 2-hour LV overloading with mechanically-induced acute aortic regurgitation (n = 4), or no load interventions (n = 6). Non-ischemic remote myocardium was processed for proteomics. Age-matched naïve pigs (n = 6) served as reference. Protein abundance was analyzed using four-group LIMMA moderated ANOVA and pairwise LIMMA moderated t-tests. These were followed by functional enrichment and STRING functional association network analysis of ANOVA-significant proteins together with exploratory screening for load-associated candidates. Results A total of 1713 proteins were identified, of which 1552 were included in the statistical analysis, and 7 remained significant after multiple-testing correction. Pairwise analyses revealed that significant protein-level differences were predominantly observed between the MI and Sham groups, whereas protein changes in response to 2-h of acutely altered LV load were limited. An exploratory screening identified six load-associated candidate proteins, with ITIH1 and MYOZ2 selected as representative candidates. Independent human transcriptomic analysis suggested disease-related context of these candidates. Conclusions Proteomic remodeling of the non-ischemic remote myocardium in response to acutely altered LV load was less prominent compared to the impact of MI. Exploratory analysis identified LV load-associated candidate proteins.
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder caused primarily by pathogenic variants in sarcomeric genes encoding β-cardiac myosin heavy chain (MYH7) and cardiac myosin binding protein-C (MYBPC3; cMyBP-C). cMyBP-C plays a central role in the modulation of contractility by interacting with the subfragment 2 (S2) region of myosin in a phosphorylation-dependent manner, thereby tuning myosin head availability. The proximal S2 region, enriched in negatively charged residues, facilitates reversible sequestration of myosin heads into the energy-conserving super-relaxed (SRX) state, which is characterized by reduced ATPase activity. Through its phosphorylation-sensitive M-domain, cMyBP-C stabilizes this inhibited state by binding S2 when myosin heads are folded back. In response to physiological stress, phosphorylation of cMyBP-C weakens this interaction, promoting release of myosin heads from the SRX state and enhancing contractility. Pathogenic mutations in MYH7 or MYBPC3 disrupt this modulatory mechanism, shifting the equilibrium toward increased myosin head availability, hypercontractility, and inefficient ATP utilization, all hallmarks of HCM. While conventional therapies do not directly target these molecular defects, recently developed myosin inhibitors such as mavacamten and aficamten demonstrate therapeutic potential by modulating sarcomere function, although their efficacy is limited to specific patient subsets. This review examines the structural and functional dynamics of the cMyBP-C–myosin S2 interaction as a key determinant of cardiac muscle contraction. We highlight roles in SRX stabilization, contractile control, and disease pathogenesis, and discuss emerging strategies, including gene therapy, targeted peptides, and protein replacement, to restore sarcomere function. A detailed molecular understanding of this interaction may inform the development of disease-modifying therapies for HCM.
Background: Sustained tachyarrhythmia is a major cause of cardiac dysfunction and can lead to tachycardia-induced cardiomyopathy (TIC). However, the role of small extracellular vesicle (sEV)-mediated intercellular communication in the pathogenesis of TIC remains poorly understood. We aimed to investigate whether sEVs derived from tachy-paced cardiomyocytes affect intracellular Ca 2+ handling in recipient cardiomyocytes. Methods and results: Cultured murine atrial cardiomyocytes (HL-1 cells) were subjected to high-frequency electrical stimulation (tachy-pacing, 10 Hz), and sEVs were isolated from the culture supernatant. sEVs derived from the tachy-paced cells and non-paced control cells were subsequently applied to neonatal mouse cardiomyocytes (NMCMs). Intracellular Ca 2+ transients, sarcoplasmic reticulum (SR) Ca 2+ content, and the expression of Ca 2+ -handling proteins were evaluated. High-frequency electrical stimulation significantly increased sEV secretion from HL-1 cells. sEVs derived from tachy-paced HL-1 cells markedly slowed Ca 2+ decay and reduced SERCA2a protein expression in recipient NMCMs. Conclusions: Our study demonstrates that sEVs derived from tachy-paced cardiomyocytes suppress SERCA2a expression, thereby leading to impaired SR Ca 2+ reuptake and prolonged Ca 2+ transients. These findings suggest that sEV-mediated signaling may contribute to Ca 2+ dysregulation during sustained tachycardia.
Background Sustained tachyarrhythmia is a major cause of cardiac dysfunction and can lead to tachycardia-induced cardiomyopathy (TIC). However, the role of small extracellular vesicle (sEV)-mediated intercellular communication in the pathogenesis of TIC remains poorly understood. We aimed to investigate whether sEVs derived from tachy-paced cardiomyocytes affect intracellular Ca2+ handling in recipient cardiomyocytes. Methods and results Cultured murine atrial cardiomyocytes (HL-1 cells) were subjected to high-frequency electrical stimulation (tachy-pacing, 10 Hz), and sEVs were isolated from the culture supernatant. sEVs derived from the tachy-paced cells and non-paced control cells were subsequently applied to neonatal mouse cardiomyocytes (NMCMs). Intracellular Ca2+ transients, sarcoplasmic reticulum (SR) Ca2+ content, and the expression of Ca2+-handling proteins were evaluated. High-frequency electrical stimulation significantly increased sEV secretion from HL-1 cells. sEVs derived from tachy-paced HL-1 cells markedly slowed Ca2+ decay and reduced SERCA2a protein expression in recipient NMCMs. Conclusions Our study demonstrates that sEVs derived from tachy-paced cardiomyocytes suppress SERCA2a expression, thereby leading to impaired SR Ca2+ reuptake and prolonged Ca2+ transients. These findings suggest that sEV-mediated signaling may contribute to Ca2+ dysregulation during sustained tachycardia.
Background Hypertrophic cardiomyopathy (HCM) is associated with mitochondrial dysfunction and oxidative stress. Objective Our goal was to determine the effects of the dual Sodium-Glucose-Linked-Transporter (SGLT) 1 and 2 inhibitor sotagliflozin (SOTA) on myocardial remodeling, diastolic function, mitochondrial gene expression and oxidative stress in mice with HCM due to the tropomyosin E180G mutation (E180G). Methods E180G and non-carrier (NC) mice 7–8 weeks old were randomized to SOTA formulated in the chow (30 mg/kg chow) or control diet (CD) for 8 weeks. Cardiac structure and function were assessed by echocardiography at baseline, and after 4 and 8 weeks of treatment. At 8 weeks mice were sacrificed to assess myocardial histology, RNA expression and oxidative stress. Results At baseline E180G mice had myocardial hypertrophy and diastolic dysfunction that worsened over the next 8 weeks. In E180G mice, treatment with SOTA for 8 weeks prevented further LV hypertrophy, decreased interstitial fibrosis, normalized diastolic function and decreased atrial size. In E180G hearts mitochondrial gene sets were downregulated and oxidative stress was increased. SOTA treatment upregulated mitochondrial gene sets and prevented the increase in oxidative stress. Upregulated fibrosis gene sets in E180G hearts were not affected by SOTA. Conclusions In a mouse model of HCM, SOTA exerts beneficial effects on myocardial structure and diastolic function which are associated with restoration of down-regulated mitochondrial gene programs and correction of oxidative stress. SOTA may be of clinical value in the treatment of patients with HCM.